GLP-1 IN NASH AND NAFLD

Reduced secretion of GLP-1 has been found in non-diabetic NAFLD and NASH patients with impaired insulin release¹ and a reduced incretin effect has been suggested to be an early sign of impaired glucose tolerance, associated with IR and obesity².
Incretin-based therapy has proven to have an effect on liver enzymes like ALT, reduces the hepatic lipid content and improves other hepatic functional markers³.

Liraglutide does not interfere in the Mercodia Total GLP-1 NL-ELISA which means that the ELISA assay is suitable for GLP-1 measurements even in samples from patients undergoing analogue treatment.

Bernsmeier, C. et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 9, e87488 (2014).
Junker, A. E., Gluud, L., Holst, J. J., Knop, F. K. & Vilsbøll, T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J. Intern. Med. 279, 485–93 (2016).
Carbone, L. J., Angus, P. W. & Yeomans, N. D. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 23–31 (2016).

Incretins

Mercodia AB